CTLA4 and melanoma: Targeting BRAF (v-raf murine sarcoma viral oncogene homolog B1), MEK (mitogen-activated protein kinase), the immune checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and programmed cell death PD-1 has improved the overall survival of melanoma patients.